MedTrace Logo

Antitumoral Activity and Safety of AEZS-108 in Women With LHRH Receptor Positive Gynecological Tumors

NCT00569257 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 85

Last updated 2011-12-13

No results posted yet for this study

Summary

The purpose of this study is to determine whether AEZS-108 shows anti-tumor activity and is tolerated in patients with gynecological tumors (ovarian / endometrial cancer) that have been shown to express receptors for the luteinizing hormone releasing hormone (LHRH)

Conditions

Interventions

DRUG

AEZS-108

intravenous infusion at a dose of 267 mg/sqm every 3 weeks, up to 6 treatment cycles

Sponsors & Collaborators

  • AGO Study Group

    collaborator OTHER

  • AEterna Zentaris

    lead INDUSTRY

Principal Investigators

  • Günter Emons, Prof.Dr.med. · Universitäts-Frauenklinik / Department of Obstetrics and Gynecology, University of Göttingen

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2011-07-31
Completion
2011-07-31

Countries

  • Bulgaria
  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00569257 on ClinicalTrials.gov